Abstract
In a retrospective study 100 patients with DSM-III-R/ICD-10 panic disorder and agoraphobia (PDA) were interviewed about the psychopharmacological, psychological and ‘alternative’ treatments they had received in the course of their illness. Patients gave global statements about how statisfied they were with the various treatments they had experienced. Many patients received treatments that have never been investigated under controlled conditions. The most common drug treatments, in descending order, were: 48% benzodiazepines, 42% tricyclic antidepressants, 32% herbal preparations, 29% neuroleptics, 7% selective serotonin reuptake inhibitors and 6% beta blockers. Of the drug prescriptions, 63% were according to international standards. Of the neuropleptics, two-thirds (63.3%) were prescribed by nonpsychiatric physicians, and only one-third by psychiatrists (33.3%). Tricyclic antidepressants were prescribed more often by psychiatrists (64.7%) than by non-psychiatrists (31.4%). Among psychological treatments, autogenic training (43% of the patients) and psychodynamic therapy (33%) were used far more frequently than behavioural/cognitive therapy (20%). These results confirm the underutilisation of available effective treatments for panic disorder (e.g. tricyclic antidepressants or behavioural therapy) and the overutilisation of treatments without proven efficacy (e.g. herbal preparations or autogenic training). Patients were most satisfied with treatments that have been proven effective in controlled studies. Among drug treatments, benzodiazepines, selective serotonin inhibitors and tricyclic antidepressants were favoured (mean on a 0–4 scale indicating effectiveness: 2.6, 2.6 and 2.4). Neuroleptics (1.4), beta-blockers (1.0) and herbal preparations (0.9) were not rated highly effective by the patients. Among psychological treatments, patients were more satisfied with behavioural/cognitive therapy (2.6) than with psychodynamic therapies (1.5). Satisfaction with autogenic training was very low (1.0). Results have to be interpreted very carefully, because many factors could not be controlled in the study: proper recollection of the applied treatments, adequate duration and dosage of the drugs, compliance of drug intake, availability of psychological treatments, adequate duration of psychological treatments, qualification level of therapists, treatment combinations and other factors. The results may have been influenced by the fact that most respondents were recruited from an outpatient anxiety-disorders unit.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders, (DSM-III), 3rd edn., American Psychiatric Press, Washington, DC
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, (DSM-III-R), 3rd edn, revised. American Psychiatric Press, Washington, DC
American Psychiatric Association (1994) Diagnostic criteria from DSM-IV. American Psychiatric Press, Washington DC
Aronson TA (1987) Is panic disorder a distinct diagnostic entity? J Nerv Ment Dis 175:584–594
Ballenger JC, Burrows GD, Du Pont RL, Lesser IM, Noyes R, Pecknold JC, Rifkin A, Swinson RP (1988) Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Arch Gen Psychiatry 45:413–422
Bandelow B (1995) The assessment of efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Intern Clin Psychopharmacol (in press)
Barlow DH (1994) Effectiveness of behavior treatment for panic disorder with and without agoraphobia. In: Wolfe BE, Maser JD (eds) Treatment of panic disorder. A consensus development conference. American Psychiatric Press, Washington, DC, pp 105–120
Black DW, Wesner R, Bowers W, Gabel J (1993) A comparison of fluvoxamine, cognitive therapy, and placebo treatment of panic disorder. Arch Gen Psychiatry 50:44–50
Breier A, Charney DS, Heninger GR (1986) Agoraphobia with panic attacks. Arch Gen Psychiatry 43:1029–1036
Clark DM (1994) Cognitive therapy for panic disorder. In: Wolfe BE, Maser JD (eds) Treatment of panic disorder. A consensus development conference. American Psychiatric Press, Washington, DC, pp 121–132
Clark DM, Salkovskis PM, Hackmann A, Middleton H, et al (1994) Cognitive therapy in panic disorder (letter). Br J Psychiatry 265: 557–559
CNCPS (Cross-National Collaborative Panic Study) (1992) Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 160:191–202
Goisman RM, Warshaw MG, Peterson LG et al. (1994) Panic, agoraphobia, and panic disorder. Data from a multicenter anxiety disorders study. J Nerv Ment Dis 182:72–79
Grawe K, Donati R, Bernauer F (1994) Psychotherapie im Wandel Von der Konfession zur Profession. Hogrefe, Göttingen
Hamilton M (1969) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55
Hoffart A, Martinsen EW (1990) Exposure-based integrated vs pure psychodynamic treatment of agoraphobic inpatients. Psychotherapy 27:210–218
Johnston DG, Troyer IE, Whitsett SF (1988) Clomipramine treatment of agoraphobic women. An eight-week controlled trial. Arch Gen Psychiatry 45:453–459
Klein DF, Ross DC, Cohen P (1987) Panic and avoidance in agoraphobia. Application of path analysis to treatment studies. Arch Gen Psychiatry 44:377–385
Klosko JS, Barlow DH, Tassinari R, Cerny JA (1990) A comparison of alprazolam and behavior therapy in treatment of panic disorder. J Consult Clin Psychol 58:77–84
Laakmann G, Blaschke D, Eissner HJ, Hippius H (1988) Niedrig dosierte Neuroleptika in der Behandlung von Angstzuständen — Ergebnisse einer Ambulanzstudie. In: Hippius H, Laakmann G (eds) Therapie mit Neuroleptika — Niedrigdosierung. Perimed, Erlangen
Marks IM, Gelder MG, Edwards G (1968) Hypnosis and desensitization for phobias: a controlled prospective trial. Br J Psychiatry 114:1263–1274
Marks IM, Gray S, Cohen D, Hill R, Mawson D, Ramm E, Stern RS (1983) Imipramine and brief therapist-aided exposure in agoraphobics having self-exposure homework. Arch Gen Psychiatry 40:153–162
Marks IM (1987) Fears, phobias and rituals. Oxford University Press, New York
Marks IM, Swinson RP, Basoglu M, et al (1993) Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Brit J Psychiatry 162:776–787
Mavissakalian M, Michelson L (1986a) Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. J Clin Psychiatry 47:117–122
Mavissakalian M, Michelson L (1986b) Two-year follow-up exposure and imipramine treatment of agoraphobia. Am J Psychiatry 143:1106–12
Munjack DJ, Crocker B, Cabe D et al. (1989) Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 9:22–27
National Institute of Health (1991) NIH Consensus Development Conference Statement, vol 9, no 2. Treatment of panic disorder. NIH, Bethesda, Maryland; September
Norton GR, Allen GE, Hilton J (1983) The social validity of treatments for agoraphobia. Behav Res Ther 21:393–399
Ravaris CL, Friedman MJ, Hauri PJ, McHugo GJ (1991) A controlled study of alprazolam and propranolol in panic disorder and agoraphobia. J Clin Psychopharmacol 11:344–350
Rosenberg R, Ottosson JO, Bech P, Mellergård M, Rosenberg NK (1991) Validation criteria for panic disorder as a nosological entity. Acta Psychiat Scand 365 (Suppl):7–17
Salzmann C (1993) Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse. J Psychiat Res 27 (Suppl 1):97–110
Shader RI, Greenblatt DJ (1993) Use of benzodiazepines in anxiety disorders. N Engl J Med 328:1398–1405
Sheehan DV, Ballenger J, Jacobsen G (1980) Treatment of endogenous anxiety with phobic, hysterical, and hypochondrial symptoms. Arch Gen Psychiatry 37:51–59
Swinson RP, Cox BJ, Woszczyna CB (1992) Use of medical services and treatment for panic disorder with agoraphobia and for social phobia. Can Med Assoc J 147:878–883
Taylor CB, King R, Margraf J, Ehlers A, Telch M, Roth WT, Agras WS (1989) Use of medication and in vivo exposure in volunteers for panic disorder research. Am J Psychiatry 146: 1423–1426
Telch MJ, Agras WS, Taylor CB, Roth WT, Gallen CC (1985) Combined pharmacological and behavioral treatment for agoraphobia. Behav Res Ther 23:325–335
World Health Organization (1978) Mental disorders: Glossary and guide to their classification in accordance with the ninth revision of the International Classification of Diseases. WHO, Geneva
World Health Organisation (1991) Tenth revision of the International Classification of Diseases, chapter V (F): Mental and behavioural disorders (including disorders of psychological development). Clinical descriptions and diagnostic guidelines. WHO, Geneva
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bandelow, B., Sievert, K., Röthemeyer, M. et al. What treatments do patients with panic disorder and agoraphobia get?. Eur Arch Psychiatry Clin Nuerosci 245, 165–171 (1995). https://doi.org/10.1007/BF02193090
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02193090